PDF(Pubmed)
Abstract：
UNASSIGNED: Atopic dermatitis (AD) is one of the most common chronic skin conditions affecting about 20% of children and 5% of adults. However, the studies assessing novel therapies for AD have been focused mainly on paediatric patients and only few studies have involved adult participants.
UNASSIGNED: To compare the treatment outcomes between the antihistamine monotherapy and combined intervention with an antihistamine agent and a cysteinyl leukotriene receptor antagonist in adult patients with atopic dermatitis.
UNASSIGNED: Patients were randomized into two groups to receive 5 mg oral desloratadine or the combined therapy with 5 mg oral desloratadine and 10 mg montelukast. Both groups were also administered topical treatment using the same protocol (topical Elocon and moisturizer). To estimate the efficacy of the implemented therapy methods, different skin health scores (SCORAD, GISS, EASI, PPNRS and DLQI) and skin functional assessment outcomes (corneometry, pH and transepidermal water loss) were evaluated before and after the treatment.
UNASSIGNED: Significant differences were revealed in compared measurement results for scales of the Extent and Severity of Eczema assessment, Global Individual Signs Score, Eczema Area and Severity Index, Pruritus Numerical Rating Scale, Dermatology Life Quality Index and Skin Functional Properties (p > 0.05).
UNASSIGNED: Comparison of data presenting the therapy outcomes in two groups showed that administration of the combined therapy was significantly more effective compared to the antihistamine monotherapy. The results revealed considerable efficacy of the combined therapy reinforced by the use of cysteinyl leukotriene receptor antagonist, montelukast.
UNASSIGNED: To compare the treatment outcomes between the antihistamine monotherapy and combined intervention with an antihistamine agent and a cysteinyl leukotriene receptor antagonist in adult patients with atopic dermatitis.
UNASSIGNED: Patients were randomized into two groups to receive 5 mg oral desloratadine or the combined therapy with 5 mg oral desloratadine and 10 mg montelukast. Both groups were also administered topical treatment using the same protocol (topical Elocon and moisturizer). To estimate the efficacy of the implemented therapy methods, different skin health scores (SCORAD, GISS, EASI, PPNRS and DLQI) and skin functional assessment outcomes (corneometry, pH and transepidermal water loss) were evaluated before and after the treatment.
UNASSIGNED: Significant differences were revealed in compared measurement results for scales of the Extent and Severity of Eczema assessment, Global Individual Signs Score, Eczema Area and Severity Index, Pruritus Numerical Rating Scale, Dermatology Life Quality Index and Skin Functional Properties (p > 0.05).
UNASSIGNED: Comparison of data presenting the therapy outcomes in two groups showed that administration of the combined therapy was significantly more effective compared to the antihistamine monotherapy. The results revealed considerable efficacy of the combined therapy reinforced by the use of cysteinyl leukotriene receptor antagonist, montelukast.
摘要：
■特应性皮炎（AD）是最常见的慢性皮肤病之一，影响约20％的儿童和5％的成人。然而,评估AD新疗法的研究主要针对儿科患者,只有少数研究涉及成年参与者.
比较成人特应性皮炎患者抗组胺单药治疗与抗组胺药和半胱氨酰白三烯受体拮抗剂联合干预的治疗结果。
■患者随机分为两组，分别接受5mg口服地氯雷他定或5mg口服地氯雷他定和10mg孟鲁司特联合治疗。两组也使用相同的方案(局部Elocon和保湿剂)施用局部治疗。为了评估实施的治疗方法的疗效，不同的皮肤健康评分(SCORAD，GISS,EASI,PPNRS和DLQI)和皮肤功能评估结果(角膜测量法，在治疗前后评估pH和经皮失水）。
■比较湿疹程度和严重程度评估的测量结果有显著差异，全球个人体征得分，湿疹面积和严重程度指数，瘙痒数值评定量表，皮肤病生活质量指数和皮肤功能特性(p>0.05)。
两组治疗结果数据的比较表明，与抗组胺药物单一疗法相比，联合疗法的给药效果明显更高。结果表明，通过使用半胱氨酰白三烯受体拮抗剂增强的联合疗法具有相当大的疗效，孟鲁司特.
比较成人特应性皮炎患者抗组胺单药治疗与抗组胺药和半胱氨酰白三烯受体拮抗剂联合干预的治疗结果。
■患者随机分为两组，分别接受5mg口服地氯雷他定或5mg口服地氯雷他定和10mg孟鲁司特联合治疗。两组也使用相同的方案(局部Elocon和保湿剂)施用局部治疗。为了评估实施的治疗方法的疗效，不同的皮肤健康评分(SCORAD，GISS,EASI,PPNRS和DLQI)和皮肤功能评估结果(角膜测量法，在治疗前后评估pH和经皮失水）。
■比较湿疹程度和严重程度评估的测量结果有显著差异，全球个人体征得分，湿疹面积和严重程度指数，瘙痒数值评定量表，皮肤病生活质量指数和皮肤功能特性(p>0.05)。
两组治疗结果数据的比较表明，与抗组胺药物单一疗法相比，联合疗法的给药效果明显更高。结果表明，通过使用半胱氨酰白三烯受体拮抗剂增强的联合疗法具有相当大的疗效，孟鲁司特.
